EU pharmacovigilance fees edge closer after member state approval
This article was originally published in SRA
EU member states have approved a compromise agreement with the European Parliament on a draft regulation for establishing the long overdue EU pharmacovigilance fee regime1.
You may also be interested in...
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.
The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.